Andrew Armstrong, MD, MSc

Christopher Wallis, MD, PhD, FRCSC

GU Oncology Now

Andrew Armstrong, MD, MSc, Duke University School of Medicine, and Christopher Wallis, MD, PhD, University of Toronto, discuss the design and implications of an AI-derived digital pathology-based biomarker to predict benefit of long-term ADT with radiotherapy in men with localized high-risk prostate, as well as HRQoL for patients with mCRPC who received abiraterone plus olaparib in the PROpel trial.Dr. Armstrong and colleagues successfully validated the first predictive biomarker of long-term ADT benefit with RT in localized high-risk prostate cancer using an AI-derived digital pathology-based platform in the phase III NRG/RTOG 9202 trial. The biomarker identified 34% of men that could derive similar benefit with short-term ADT, avoiding the side effects of prolonged ADT, and 43% of intermediate-risk men who would benefit from long-term ADT.Data from the final prespecified cutoff for PROpel showed a significant delay in rPFS for patients receiving abiraterone plus olaparib vs abiraterone plus placebo. Abiraterone plus olaparib showed no difference in HRQoL, suggesting patients can derive clinical benefit from this combination while maintaining a similar HRQoL compared with a current standard-of-care treatment.<a href="https://guoncologynow.com/category/asco-2023" target="_blank" rel="noopener">View more ASCO 2023 videos</a>.

Drs. Armstrong, Wallis on AI Biomarkers and HRQoL for Localized Prostate Cancer, mCRPC

American Society of Clinical Oncology 2023 Annual Meeting

ASCO 2023

Drs. Armstrong and Wallis discuss the design and implications of an AI-derived digital pathology-based biomarker for localized high-risk prostate.

Drs. Armstrong, Wallis on AI Biomarkers and HRQoL for Prostate Cancer

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe